La vendita allo scoperto per Altimmune dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Altimmune. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Altimmune (NASDAQ:ALT) Azioni, Report sulle vendite allo scoperto

Altimmune

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Altimmune Inc

AltLayer - United States Dollar

ALT11M2507 - United States Dollar

ALT2612 - United States Dollar

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTURAS MINERALS CORP by Alturas Minerals Corp.

Alturas Minerals Corp

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

Arcadium Lithium PLC

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

Altair Engineering Inc. - Class A Common Stock

Altair Engineering Inc

ALT5 Sigma Corp

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome
Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8mpdWoq0vRuruY-wgKR7jeGdXm_k2idcer7Db_E2cxWdj4yekH1YRRXMjYkm08SS2fPpYVFEMZXywtJ8hQ3K1A==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting&#xAE; of the&nbsp;American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.
The new data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) ≥10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.
The goal of the study was to characterize changes in the lipid profile of patients before and after treatment with pemvidutide. In this study of 50 subjects, treatment with pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated with MASH and implicated in cardiovascular and atherosclerotic disease. In particular, a rapid and significant reduction in small atherogenic LDL particles was observed in the 1.8 mg and 2.4 mg dose groups compared to placebo.

Biotech

News

General

Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

High-rolling investors have positioned themselves bullish on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ALT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Altimmune. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $41,891, and 7 calls, totaling $550,860.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.0 to $12.0 for Altimmune over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Altimmune options trades today is 910.14 with a total volume of 3,378.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Altimmune's big money trades within a strike price range of $7.0 to $12.0 over the last 30 days.
<h3>Altimmune Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731520954_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$12.00</td>
<td>$319.6K</td>
<td>409</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$10.00</td>
<td>$71.9K</td>
<td>3.5K</td>
<td>390</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$7.50</td>
<td>$37.0K</td>
<td>370</td>
<td>100</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$3.5</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$7.00</td>
<td>$33.0K</td>
<td>375</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Altimmune</h3>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
In light of the recent options history for Altimmune, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Altimmune</h3>
<ul>
<li>Currently trading with a volume of 7,319,895, the ALT's price is up by 6.15%, now at $10.07. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 133 days.</li>
</ul>
<h3>What Analysts Are Saying About Altimmune</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $26.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Buy, setting a price target of $26. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Altimmune, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Altimmune Unusual Options Activity For November 13

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INCY

PTGX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/news/earnings/24/11/41900813/tyson-foods-q4-earnings-revenue-and-eps-beat-beef-gains-outshine-chicken-dip-more">upbeat quarterly earnings</a>.
The company reported fourth-quarter adjusted earnings per share of 92 cents beating the street view 69 cents. Quarterly revenues of $13.565 billion (+1.6%) outpaced the analyst consensus of $13.392 billion.
Tyson shares jumped 8.5% to close at $63.79 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares surged 39.8% to $2.2781. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 33.6% to $1.5827.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 30.2% to $9.57 after the company reported better-than-expected third-quarter financial results. Also, UBS initiated coverage on the stock with a Buy rating and announced a price target of $26.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) gained 25.5% to $112.97 following strong quarterly sales.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) rose 19% to $4.1300.</li>
<li>Priority Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) gained 16.7% to $8.63.</li>
<li>Alight, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) shares rose 13.6% to $8.48 after the company reported better-than-expected third-quarter sales results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates..</li>
<li>Grab Holdings Limite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 11.7% to $4.8990 after the company reported better-than-expected quarterly financial results and raised its FY25 revenue guidance above estimates.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) gained 10.8% to $108.00 after the company reported better-than-expected third-quarter sales, despite a miss on EPS estimates..</li>
<li>The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) rose 5.4% to $47.57 after UBS upgraded the stock from Sell to Neutral and raised its price target from $31 to $46.</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) gained 4.4% to $129.21 following third-quarter results. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Movers

Trading Ideas

ALIT

GRAB

NWTN

PRTH

RVNC

SHOP

TSHA

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday

WIIM

Altimmune shares are trading higher after the company reported better-than-expected Q3 financial results. Also, UBS initiated coverage on the stock with a Buy rating and announced a price target of $26.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Redburn Atlantic analyst Timm Schulze-Melander initiated coverage on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy rating and announced a price target of $178. Nvidia shares closed at $145.26 on Monday. <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Matthew Harrigan initiated coverage on VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) with a Buy rating and announced a price target of $48. VEON shares closed at $33.17 on Monday. <a href="https://www.benzinga.com/quote/VEON/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announced a price target of $26. Altimmune shares closed at $7.35 on Monday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Capital One analyst Dan Guglielmo initiated coverage on FrontView REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) with an Overweight rating and announced a price target of $22. FrontView REIT shares closed at $18.97 on Monday. <a href="https://www.benzinga.com/quote/fvr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle initiated coverage on Sagimet Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) with a Buy rating and announced a price target of $12. Sagimet Biosciences shares closed at $5.85 on Monday. <a href="https://www.benzinga.com/quote/sgmt/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12134258/image-121-1024x557.png" alt="" class="wp-image-643639" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12134258/image-121-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12134258/image-121-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12134258/image-121-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12134258/image-121.png 1186w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Initiation

NVDA

SGMT

VEON

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

UBS analyst Eliana Merle initiates coverage on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announces Price Target of $26.

UBS Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $26

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.36) by 11.11 percent. The company reported quarterly sales of $5.000 thousand which beat the analyst consensus estimate of $833.330 by 500.00 percent. This is a 98.62 percent decrease over sales of $362.000 thousand the same period last year.

Earnings

Earnings Beats

Altimmune Q3 2024 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $5.000K Beat $833.330 Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Management

Altimmune Appoints Greg Weaver As Chief Financial Officer

Altimmune shares are trading higher after the company announced the completion of its end of Phase 2 meeting with the FDA for Pemvidutide in obesity treatment. The company and FDA are now aligned on key efficacy and safety measures to be studied in its Phase 3 program.

Altimmune Announces Completion Of End-of-Phase 2 Meeting With FDA For Pemvidutide In Obesity Treatment; Company And Agency Aligned On Key Efficacy And Safety Measures To Be Studied In Phase 3 Program

<a href="https://www.globenewswire.com/Tracker?data=gn2ovBju6Frioeal4FWhYyaxaJz-S4EnlwGwo1RdtQAm_BVGEgZMa4Dyyp5jZjcvkSZ53kFs_DlYMRe89QD4Qw==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting&#xAE; 2024 of the American Association for the Study of Liver Diseases (AASLD) in San Diego, CA taking place November 15-19, 2024. The data were derived from Altimmune's 12-week Phase 1b randomized, placebo-controlled study in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), a precursor to the more serious metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed enrollment in a Phase 2b efficacy trial of pemvidutide in patients with biopsy-confirmed F2/F3 MASH, with topline data expected in the second quarter of 2025.

Altimmune To Present New Data On The Lipidomic Profile In Subjects Treated With Pemvidutide At The Liver Meeting 2024

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.
These new drugs, expected to hit the market by 2029, aim to surpass current efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could change the market landscape despite Novo and Lilly&#8217;s current hold on the sector.
According to a <a target="_blank" href="https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf" rel="noreferrer noopener">report</a> by Morningstar, the global GLP-1 market is poised to reach $200 billion by 2031, with obesity treatment expected to account for 68% of sales.
While Novo Nordisk and Eli Lilly are projected to retain two-thirds of this market, driven by first-mover advantage and robust pipelines, new competitors could claim significant market share.
Public and private biopharma firms are increasingly focusing on cardiometabolic drug development, with 16 new obesity drugs potentially launching by 2029 the report added.
This pipeline includes candidates from major players such as <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">Roche Holdings AG</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and private companies like Boehringer Ingelheim.
Roche released topline results from the ongoing multi-part Phase 1 trial for CT-996, showing data better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>. Despite Novo Nordisk and Eli Lilly&#8217;s strong market positions, some analysts view their stocks as overvalued.
Achieving the market penetration needed to justify their current valuations would require near-unprecedented success, including capturing 75% of the U.S. obesity market and 95% of the global market by 2031.
Additionally, maintaining stable pricing seems unlikely, with increased competition and innovation expected to put downward pressure on drug prices.
Supply chain issues pose further challenges. Both companies face difficulties in manufacturing peptide-based drugs at scale, such as Wegovy and Zepbound.
While oral peptide drugs like high-dose Novo Nordisk&#8217;s Rybelsus and Viking Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37937068/viking-therapeutics-investigational-oral-obesity-drug-shows-reduced-weight-in-small-study" rel="noreferrer noopener">VK2735 offer alternatives</a>, they may be even harder to supply due to the higher doses required for efficacy.
Small molecule drugs, like Lilly&#8217;s orforglipron and Pfizer&#8217;s<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener"> danuglipron</a>, offer the best potential for scalable production, promising more streamlined manufacturing processes.
New entrants to the obesity drug market are pushing the envelope, with drug candidates from companies like Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and Zealand Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) on the horizon.
In a phase 1 study, Amgen&#8217;s AMG 133 showed an acceptable safety and tolerability profile and pronounced <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">dose-dependent weight loss</a>.&nbsp;
Altimmune said the body composition study of pemvidutide showed preservation of lean mass, with 25.5% of weight loss derived from lean mass and 74.5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958653/why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday" rel="noreferrer noopener">from adipose tissue</a>.
These next-generation drugs could challenge the dominance of Novo and Lilly, especially if they offer better efficacy or fewer side effects.
However, Wegovy and Zepbound&#8217;s entrenched positions and ongoing innovation may keep Novo and Lilly at the forefront for the foreseeable future.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" target="_blank" rel="noreferrer noopener">GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Analyst Color

Large Cap

Health Care

RHHBY

ZLDPF

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names

<ul>
<li>IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025.</li>
<li>End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024.</li>
<li>Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024</li>
</ul>

Altimmune Has Completed Patient Enrollment In IMPACT Phase 2B Biopsy-driven Trial Evaluating Pemvidutide In Metabolic Dysfunction-associated Steatohepatitis, Top-line Efficacy Data Expected In Q2 2025

Altimmune shares are trading higher after the company presented data from its Phase 2 MRI-based body composition sub-study of pemvidutide in subjects overweight or with obesity.

<a href="https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html" title="https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html">https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html</a>

Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%

In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was&nbsp;21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was only&nbsp;19.9%. In addition to lean mass preservation, there was a preferential reduction of VAT, the adipose tissue associated with cardiovascular risk.
At the 2.4mg dose of pemvidutide, VAT was reduced by&nbsp;25.6%&nbsp;at Week 48 compared to a&nbsp;20.1%&nbsp;loss in subcutaneous adipose tissue.

Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Altimmune, presenting an average target of $19.25, a high estimate of $25.00, and a low estimate of $12.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1724349614_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Altimmune by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Altimmune. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Altimmune's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Altimmune's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Altimmune</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>A Deep Dive into Altimmune's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Altimmune's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -16.67%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Altimmune's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -492800.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE excels beyond industry benchmarks, reaching -15.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Altimmune's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.62%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 4 Analyst Evaluations For Altimmune

B. Riley reiterates a Buy rating on Altimmune (ALT) with a $20 price target following the Q3 report. The company provided key pipeline updates rela...

Altimmune provided key pipeline updates with Q3 report, says B. Riley

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $12.00. Patri...

Altimmune's Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick Trucchio

After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor agonist in...

Altimmune's pemvidutide looks differentiated among GLP-1s, says H.C. Wainwright

Bullish option flow detected in Altimmune (ALT) with 16,820 calls trading, 6x expected, and implied vol increasing almost 4 points to 128.62%. Nov-...

Altimmune call volume above normal and directionally bullish

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Charter (CHTR) agreed to acquire Liber...

Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Comments

Altimmune

Vendite allo scoperto

Altimmune (NASDAQ:ALT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO